secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silexion Therapeutics Corp (SLXN)
CIK:        0002022416
Form:       8-K
Filed at:   2025-09-25T23:59:59+00:00
Accession:  0001178913-25-003374
Event type: regulatory
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Silexion Therapeutics regains Nasdaq compliance; subject to one-year monitor
----------------------------------------------------------------------------

- Received Nasdaq compliance letter on Sep 23, 2025 for equity (≥$2.5M) and minimum bid price ($1.00) requirements.
- Financing transactions increased shareholders' equity by $10.3M to ~$9.41M as of Sep 15, 2025.
- 1-for-15 reverse stock split on Jul 29, 2025 brought bid price above $1.00.
- Subject to mandatory panel monitor until Sep 23, 2026; any future non-compliance may lead to immediate delisting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2022416/000117891325003374/0001178913-25-003374-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2022416/000117891325003374/zk2533805.htm
  HTML page:      https://secwatch.observer/filing/0001178913-25-003374

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer